Efficacy of citalopram on climacteric symptoms

Kalay, Aysegul E.; Demır, Berfu; Haberal, Alı; Kalay, Mustafa; Kandemir, Ömer

doi:10.1097/01.gme.0000243571.55699.4a

Cited by 47 publications

(37 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We also extracted hot flashes/vasomotor symptoms assessed by scores (e.g., hot flash score, 10 vasomotor score, 11 modified Kupperman index, 20 Rand mood score, 21 hot flashrelated daily interference scale 22 and menopausal rating score 23 ) whenever available and from those studies that did not report daily hot flash frequency.…”

Section: Summary Of Measuresmentioning

confidence: 99%

“…Nevertheless, studies of SSRIs have demonstrated mixed results; some studies demonstrated benefit by reducing hot flashes by 50-60 % while others reported no effect. [9][10][11] Therefore, we conducted a systematic review to synthesize and summarize the best available evidence on the use of SSRIs to treat hot flashes in healthy menopausal women. The aim of this comparative effectiveness review is to evaluate the efficacy and side effect profile to aid in decision making.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

SSRIs for Hot Flashes: A Systematic Review and Meta-Analysis of Randomized Trials

et al. 2013

View full text Add to dashboard Cite

BACKGROUND: Hot flashes are the most commonly reported vasomotor symptom during the peri-and early post-menopausal period. OBJECTIVES: To systematically review, appraise and summarize the evidence of the impact of different SSRIs on peri-menopausal hot flashes in healthy women in randomized, controlled trials. METHODS: A comprehensive literature search was conducted of MEDLINE™, EMBASE, the Cochrane Central Register of Controlled Trials, Web of Science and Scopus through March 2013. Two independent reviewers selected studies and extracted data. Random effects meta-analysis was used to pool outcomes across studies, and Bayesian mixed treatment methods were used to rank SSRIs in terms of effectiveness. RESULTS: We included a total of 11 randomized controlled trials with good methodological quality enrolling 2,069 menopausal and post-menopausal women (follow-up 1-9 months, mean age 36-76 years, mean time since menopause 2.3-6.6 years). Compared with placebo, SSRIs were associated with a statistically significant decrease in hot flash frequency (difference in means −0.93; 95 % CI −1.46 to −0.37; I 2 = 21 %) and severity assessed by various scales (standardized difference in means −0.34; 95 % CI −0.59 to −0.10; I 2 = 47 %). Adverse events did not differ from placebo. Mixed treatment comparison analysis demonstrated the superiority of escitalopram compared to other SSRIs in terms of efficacy. CONCLUSION: SSRI use is associated with modest improvement in the severity and frequency of hot flashes but can also be associated with the typical profile of SSRI adverse effects.

show abstract

Section: Summary Of Measuresmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

SSRIs for Hot Flashes: A Systematic Review and Meta-Analysis of Randomized Trials

et al. 2013

View full text Add to dashboard Cite

show abstract

“…This study also recommended citalopram as a treatment for hot flashes [19]. Another research compared the separate impacts of citalopram and venlafaxine on hot flashes, and found citalopram to be more effective in this respect [20]. The study on hot flashes due to niacin intake proved that aspirin taken with niacin would decrease hot flashes and general body temperature [25].…”

Section: Discussionmentioning

confidence: 99%

“…Considering the significant difference observed for the simultaneous effects of these two drugs on hot flashes, it could be concluded that the efficacy of citalopram plus aspirin is higher than citalopram alone. Other studies had previously established the separate positive effects of citalopram and aspirin on reducing hot flashes [18][19][20][21][22]. Therefore, if these drugs could separately alleviate hot flashes, their simultaneous use was expected to leave a higher impact.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of Citalopram and Aspirin on Hot Flashes and Quality of Life in Premenopausal Women with Breast Cancer: A Randomized Double-blind Clinical Trial

Najafi

Baktashian

Ebrahimi

et al. 2016

mcij

View full text Add to dashboard Cite

Introduction: Over 70% of Iranian breast cancer patients are reported to have experienced an earlier menopause after chemotherapy. Due to the high and prevalent appearance of amenorrhea, this study focused on the efficacy of citalopram plus aspirin, compared to citalopram plus a placebo on cancerous women with chemotherapy-induced amenorrhea symptoms in premenopausal stages. Methods: In this randomized clinical trial study, 32 participants were randomly allocated to treatment (receiving citalopram and aspirin), and 28 to control (receiving citalopram and placebo) groups. Participants were selected from patients referring to Breast Cancer Research Center of ACECR, and Seyyed-o-Shohada Hospital in Isfahan, Iran. To assess their functional, physical, emotional and socio-familial well-being, as well as their hot flashes, Functional Assessment of Cancer Therapy-General questionnaires were used, while the effect of treatment was measured using paired t-test and Wilcoxon signed-rank test. Results:The means of participants′ ages were 45.03 ± 5.1 and 44.7 ± 5.3 in treatment and control groups, respectively. Hot flashes decreased in both groups to a statistically significant degree, while no significant differences were observed in functional and sociofamilial well-being of participants before and after the treatment. The treatment group also displayed significantly improved emotional and physical well-being statuses after the treatment. Conclusions:The study demonstrated that premenopausal women undergoing chemotherapy for breast cancer experience disturbing symptoms such as hot flashes, and lower emotional and physical well-being, which can largely be treated with citalopram and aspirin. Relevant specialists and physicians could thus prescribe this drug regimen to alleviate these major symptoms.

show abstract

Efficacy of Escitalopram for Hot Flashes in Healthy Menopausal Women

Freeman

Guthrie

Caan

et al. 2011

JAMA

214

153

View full text Add to dashboard Cite

ORMONAL AGENTS HAVE BEEN the predominant therapy for menopausal hot flashes, but their use decreased substantially following the shifts in riskbenefit ratios that were identified in the Women's Health Initiative Estrogen plus Progestin randomized controlled trial. 1,2 However, no other treatments have US Food and Drug Administration approval for menopausal hot flashes, and the efficacy of alternative pharmacologic and nonpharmacologic agents is inconclusive. [3][4][5] Selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs and SNRIs) have been investigated for hot flash treatment with mixed results [6][7][8][9][10][11] ; a pooled analysis of 7 SSRI and SNRI studies showed that decreases in hot flash scores ranged from 3% to 41% compared with placebo. 6 Differences among the serotonergic antidepressants, 11 study popu-

show abstract

Efficacy of citalopram on climacteric symptoms

Cited by 47 publications

References 21 publications

SSRIs for Hot Flashes: A Systematic Review and Meta-Analysis of Randomized Trials

SSRIs for Hot Flashes: A Systematic Review and Meta-Analysis of Randomized Trials

Effect of Citalopram and Aspirin on Hot Flashes and Quality of Life in Premenopausal Women with Breast Cancer: A Randomized Double-blind Clinical Trial

Efficacy of Escitalopram for Hot Flashes in Healthy Menopausal Women

Contact Info

Product

Resources

About